Skip to Main content Skip to Navigation
Journal articles

A hemophilia A mouse model for the in vivo assessment of emicizumab function

Abstract : The bispecific antibody emicizumab is increasingly used for hemophilia A treatment. However, its specificity for human factors IX and X (FIX and FX) has limited its in vivo functional analysis to primate models of acquired hemophilia. Here, we describe a novel mouse model that allows emicizumab function to be examined. Briefly, FVIII-deficient mice received IV emicizumab 24 hours before tail-clip bleeding was performed. A second infusion with human FIX and FX, administered 5 minutes before bleeding, generated consistent levels of emicizumab (0.7-19 mg/dL for 0.5-10 mg/kg doses) and of both FIX and FX (85 and 101 U/dL, respectively, after dosing at 100 U/kg). Plasma from these mice display FVIII-like activity in assays (diluted activated partial thromboplastin time and thrombin generation), similar to human samples containing emicizumab. Emicizumab doses of 1.5 mg/kg and higher significantly reduced blood loss in a tail-clip-bleeding model using FVIII-deficient mice. However, reduction was incomplete compared with mice treated with human FVIII concentrate, and no difference in efficacy between doses was observed. From this model, we deducted FVIII-like activity from emicizumab that corresponded to a dose of 4.5 U of FVIII per kilogram (ie, 9.0 U/dL). Interestingly, combined with a low FVIII dose (5 U/kg), emicizumab provided enough additive activity to allow complete bleeding arrest. This model could be useful for further in vivo analysis of emicizumab.
Document type :
Journal articles
Complete list of metadata

Cited literature [24 references]  Display  Hide  Download
Contributor : Cécile Denis Connect in order to contact the contributor
Submitted on : Thursday, September 10, 2020 - 9:17:17 AM
Last modification on : Saturday, July 3, 2021 - 12:17:30 AM
Long-term archiving on: : Thursday, December 3, 2020 - 2:04:04 AM


Ferrière et al 2020.pdf
Files produced by the author(s)



Stephen Ferrière, Ivan Peyron, Olivier D. Christophe, Charlotte Kawecki, Caterina Casari, et al.. A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood, American Society of Hematology, 2020, 136 (6), pp.740-748. ⟨10.1182/blood.2019004334⟩. ⟨inserm-02916896⟩



Record views


Files downloads